JW (Cayman) Therapeutics Co. Ltd (Stock Code: 2126) disclosed that on January 16, 2026, it granted a total of 2,600,000 share options and 650,000 restricted share units (RSUs) to four grantees, including an executive Director and Chief Executive Officer, Mr. Feng Tian, as well as other eligible employees. According to the announcement, Mr. Tian received 1,500,000 share options and 400,000 RSUs, both of which adopt a time-based vesting schedule without additional performance targets. The other participants must meet specific performance evaluations before their respective options or RSUs vest.

The exercise price for the options is HK$2.92 per share, and the validity period for both the options and RSUs extends from January 16, 2026, to January 15, 2036. Under the vesting schedule, a portion of the total options and RSUs typically vests in increments over a two- to four-year period following the specified commencement dates. A clawback mechanism applies under circumstances such as serious misconduct or termination of employment due to applicable reasons, among others.

The Board, including independent non-executive Directors, approved these grants, with Mr. Tian abstaining from voting on his own allocation. The announcement states that these transactions are fully exempt from shareholders’ approval requirements under Chapter 14A of the Listing Rules. The Company considers these grants in line with its existing share-based incentive schemes and consistent with its overall objectives. As of the date of the announcement, the remaining share reserves under the respective schemes are 24,442,388 shares for the Post-IPO Incentivization Scheme and 4,073,755 shares for the Post-IPO Restricted Share Unit Scheme.